Medical Condition News

RSS

New antibody with SGN-35 drug produces remission in Hodgkin lymphoma

An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38 percent of patients with relapsed or therapy-resistant Hodgkin lymphoma enrolled in a phase I clinical trial, investigators report in the Nov. 4 issue of the New England Journal of Medicine.

4 Nov 2010

Positive results from Lithera's LIPO-102 Phase IIb clinical study for abdominal fat reduction

Lithera, Inc. today announced positive results from a Phase IIb clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction.

4 Nov 2010

Aduro receives $442,000 grant under QTDP program to support Listeria-based immunotherapy platform

Aduro BioTech announced today that it has been awarded two cash grants totaling approximately $442,000 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

4 Nov 2010

BioCurex files patent for synthetic peptide in RECAF test

BioCurex, Inc. today announced that it has filed a new patent within the Patent Cooperation Treaty, which presently includes 142 countries.

4 Nov 2010

EDP Biotech receives $244,000 grant under QTDP program for colon cancer blood test

EDP Biotech Corporation was awarded a $244,000 grant from the federal government under the Qualifying Therapeutic Discovery Project program as a result of the company's work in the development of their ColoMarker test, an early detection blood test for colon cancer.

4 Nov 2010

Aeolus receives $489,000 grant under QTDP program for two lead compounds

Aeolus Pharmaceuticals, Inc. today announced that it has been awarded a total of approximately $489,000 under the Qualifying Therapeutic Discovery Grant Program (QDTP) administered by the Internal Revenue Service and the Department of Health and Human Services.

4 Nov 2010

Bristol-Myers Squibb and Simcere partner to co-develop oncology compound

Bristol-Myers Squibb Company and Simcere Pharmaceutical Group, a leading pharmaceutical company in China, today announced an innovative strategic partnership to co-develop BMS-817378, a preclinical small molecule MET/VEGFR-2 inhibitor.

4 Nov 2010

New cyber-database enables access to information on lymphedema

Lymphedema is a chronic condition that causes swelling of the limbs and affects physical, mental and social health. It commonly occurs in breast cancer survivors and is the second-most dreaded effect of treatment, after cancer recurrence. Every day, researchers throughout the world learn more about the condition and how it can be treated. Now, University of Missouri researchers are developing a place in cyberspace where relevant and timely information can be easily stored, searched, and reviewed from anywhere with the goal of improving health care through the availability of up-to-date, evidence-based research.

4 Nov 2010

Spectrum Pharmaceuticals receives $977,900 grant under QTDP program

Spectrum Pharmaceuticals, Inc. a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that it has been awarded grants totaling $977,900 under the Qualifying Therapeutic Discovery Project (QTDP) Program administered under section 48D of the Internal Revenue Code.

4 Nov 2010

Single injection of morphine to fight persistent pain reduces testosterone level: Research

A single injection of morphine to fight persistent pain in male rats is able to strongly reduce the hormone testosterone in the brain and plasma, according to a new paper published in Molecular Pain.

4 Nov 2010

Synageva receives $2.3 million under QTDP program

Synageva BioPharma Corp., a privately held biopharmaceutical company developing novel treatments for rare diseases, today announced that the US Treasury Department awarded approximately $2.3 million to Synageva BioPharma as part of the Qualifying Therapeutic Discovery Project Program.

4 Nov 2010

SPRC receives funds from SAMHSA to focus on populations at high risk for suicide

In the United States, suicide claims over 34,000 lives annually, the equivalent of 94 suicides per day; one suicide every 15 minutes. To address this national crisis the Substance Abuse and Mental Health Services Administration (SAMHSA) is awarding a total of up to $22.4 million in additional funds over the course of the next five years to the Suicide Prevention Resource Center (SPRC).

4 Nov 2010

Scientists discover gene variant that rewires brain's circuitry in neurological disorders

Many gene variants have been linked to autism, but how do these subtle changes alter the brain, and ultimately, behavior. Using a blend of brain imaging and genetic detective work, scientists at UCLA's David Geffen School of Medicine and Semel Institute for Neuroscience and Human Behavior are the first to illustrate how a gene variant tied to autism rewires the brain.

4 Nov 2010

BioSpecifics receives $426,000 grant under QTDP Program

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that it has received $426,000 in grant funding under the Qualifying Therapeutic Discovery Project (QTDP) Program. The program, funded through the US Patient Protection and Affordable Care Act of 2010, supports therapeutic discovery programs.

4 Nov 2010

Biogen Idec and Cardiokine terminate lixivaptan collaboration

Biogen Idec and Cardiokine, Inc. today announced that they have agreed to dissolve their collaboration on lixivaptan. The termination of the collaboration, which began in 2007, triggers the return of all rights to lixivaptan to Cardiokine.

4 Nov 2010

Affymax receives $244,479.25 in funding under QTDP program

Affymax, Inc. today announced that it has been awarded $244,479.25 in funding under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program established under Section 48D of the Internal Revenue Code.

4 Nov 2010

PolyMedix receives $488,958 grants under QTDP program

PolyMedix, Inc. a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, announced today that it has been awarded two cash grants totaling $488,958 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

4 Nov 2010

Acton submits Manufacturing Supplement to FDA for AEROSPAN Inhalation Aerosol

Acton Pharmaceuticals, Inc. today announced that it has submitted to the U.S. Food and Drug Administration (FDA), a Manufacturing Supplement to the previously approved AEROSPAN Inhalation Aerosol NDA.

4 Nov 2010

New simple blood test may help diagnose Niemann-Pick type C disease

A fatal genetic disorder that frequently takes years to diagnose may soon be detectable with a simple blood test, researchers at Washington University School of Medicine in St. Louis and the National Institutes of Health (NIH) report this week in Simple blood test may diagnose deadly Niemann-Pick type C disease.

4 Nov 2010

Cerebral palsy risk doubles with IVF: Study

There is now evidence that rates of cerebral palsy are higher among children born via in vitro fertilization (IVF). There has been speculation that the parents’ infertility could be a reason but this new study is the first that links the procedure to the condition.

3 Nov 2010